Semaglutida (Wegovy) para el manejo de peso: anlisis clnico 2026 Actualizado: 07 de enero de 2026 DESCARGO DE RESPONSABILIDAD MDICA: Este artculo es una revisin informativa sobre farmacologa clnica
Patients should not feel discouraged if their initial symptoms were described informally
Abrami M, Karai Z, emanjski M, Vukeli B, Jajanin-Jozi N
You might also notice some temporary reactions at the injection site, like redness, swelling, or itching
Prescribers who rely exclusively on commercial products are one shortage away from having no options for their patients
And there was obviously nothing that has to do with cost, and my patients can't benefit from a drug they can't afford. Lundberg also mentioned the concerning discontinuation rate between 20% and 30%, which was similar between oral semaglutide and placebo